Wall Street brokerages forecast that Tilray Inc (NASDAQ:TLRY) will report ($0.35) earnings per share for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Tilray’s earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.46). Tilray reported earnings of ($0.29) per share during the same quarter last year, which would indicate a negative year over year growth rate of 20.7%. The business is expected to announce its next quarterly earnings report on Monday, March 16th.
On average, analysts expect that Tilray will report full-year earnings of ($1.39) per share for the current year, with EPS estimates ranging from ($1.44) to ($1.29). For the next financial year, analysts expect that the company will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.56) to ($0.60). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Tilray.
Tilray (NASDAQ:TLRY) last announced its earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.05). The company had revenue of $51.10 million for the quarter, compared to analyst estimates of $49.57 million. Tilray had a negative return on equity of 40.30% and a negative net margin of 97.39%. The firm’s quarterly revenue was up 411.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.08) earnings per share.
Several equities analysts have recently issued reports on the company. Roth Capital reaffirmed a “hold” rating on shares of Tilray in a report on Thursday, December 12th. MKM Partners dropped their price objective on Tilray from $34.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, November 14th. ValuEngine upgraded Tilray from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Piper Jaffray Companies dropped their price objective on Tilray from $72.00 to $31.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Finally, Cantor Fitzgerald initiated coverage on Tilray in a research note on Monday, November 4th. They issued a “neutral” rating and a $20.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and five have assigned a buy rating to the company. Tilray has an average rating of “Hold” and a consensus target price of $41.33.
Tilray stock traded up $0.57 during midday trading on Friday, reaching $21.00. The stock had a trading volume of 5,542,929 shares, compared to its average volume of 5,661,651. Tilray has a 12 month low of $15.01 and a 12 month high of $89.88. The company has a market capitalization of $2.13 billion, a P/E ratio of -25.60 and a beta of 3.87. The company has a fifty day moving average price of $17.68 and a two-hundred day moving average price of $27.77. The company has a current ratio of 2.54, a quick ratio of 1.69 and a debt-to-equity ratio of 1.05.
In other news, CEO Brendan Kennedy sold 100,000 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $16.40, for a total transaction of $1,640,000.00. Following the transaction, the chief executive officer now directly owns 4,666,740 shares of the company’s stock, valued at $76,534,536. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael Auerbach sold 31,875 shares of Tilray stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $19.05, for a total transaction of $607,218.75. Following the transaction, the director now owns 31,875 shares of the company’s stock, valued at $607,218.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 231,875 shares of company stock worth $4,077,219. Company insiders own 3.40% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Alpine Global Management LLC bought a new stake in shares of Tilray during the fourth quarter valued at approximately $428,000. Gainplan LLC purchased a new position in shares of Tilray during the 4th quarter valued at $171,000. Man Group plc purchased a new stake in Tilray in the 3rd quarter worth $974,000. Baker Avenue Asset Management LP lifted its stake in Tilray by 225.5% in the 3rd quarter. Baker Avenue Asset Management LP now owns 17,900 shares of the company’s stock worth $442,000 after purchasing an additional 12,400 shares in the last quarter. Finally, Penserra Capital Management LLC bought a new stake in shares of Tilray in the 3rd quarter worth about $121,000. Hedge funds and other institutional investors own 8.61% of the company’s stock.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
See Also: How to interpret the current ratio
Get a free copy of the Zacks research report on Tilray (TLRY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.